Novartis' Kesimpta Goes Up Against Roche's Ocrevus In MS

The anti-CD20 monoclonal antibody was approved by the US FDA for relapsing multiple sclerosis, bringing a new treatment to the crowded therapeutic area – with the benefit of self-administration. 

Businessman and businesswoman armwrestling at the office table, maintaining eye contact, trying to get leadership, fighting for equal rights for women, business competitors in the marketplace
Novartis prepares to face off with Roche in multiple sclerosis with Kesimpta • Source: Shutterstock

More from Neurological

More from Therapy Areas